Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 2/28/19 → 11/7/22 |
Funding
- Merck Sharp & Dohme Corporation: $138,368.00
A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer
- Arnold, Susanne (PI)